# Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

> **NCT02035787** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Complex Atypical Hyperplasia
- Endometrial Cancer

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02035787
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-27
- **Primary completion:** 2023-10-12
- **Final completion:** 2024-04-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035787, "Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02035787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*